9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

Estimated reading time: 1 min

Condition: Mesothelioma

Estimated Enrollment: 77

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Time to progression (TTP) from first day of treatment until first observation of disease progression or death due to any cause or the last date the patient was known to be progression free or alive.,  Response rate (RR) assessed according to modified RECIST criteria for Malignant Pleural Mesothelioma.,  Overall survival (OS) computed as the time between the first day of treatment and the date of death or the last date the patient was known to be alive.,

Interventions: Bevacizumab, Pemetrexed, Carboplatin,

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: November 2010

Completion Date: November 2010

Last  Posted Date: September 2, 2011

Location: Istituto Clinico Humanitas, Rozzano, Milan, Italy

Website Link: https://ClinicalTrials.gov/show/NCT00407459

Was this article helpful?
Dislike 0